# US 2025/0367140 A1 · Methods for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367140 A1
- Document ID: US20250367140A1
- Status: Published application
- Kind: A1
- Application number: 19/297,614
- Filed: 2025-08-12
- Published: 2025-12-04
- Earliest claimed: 2015-04-29
- Assignees: Radius Pharmaceuticals, Inc.
- Applicants: Radius Pharmaceuticals, Inc.
- Inventors: Gary HATTERSLEY
- Web page: https://patentgrep.com/patent/US20250367140A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of treating one or more tumors by administering to the subject a therapeutically effective amount of a combination of RAD1901 or solvates (e.g., hydrate) or salts thereof and one or more second therapeutic agent(s) (e.g., everolimus). The cancer is an estrogen-dependent cancer, such as breast cancer, ovarian cancer, colon cancer, endometrial cancer, or prostate cancer.

## Claims

### Claim 1

A method of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha-positive cancer comprising administering to said subject a therapeutically effective amount of a combination of everolimus and RAD1901 having the structure:
or a salt or solvate thereof.

### Claim 2

A method of inhibiting tumor growth or producing tumor regression in a subject having a mutant estrogen receptor alpha-positive cancer comprising administering to said subject a therapeutically effective amount of a combination of everolimus and RAD1901 having the structure:
or a salt or solvate thereof.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the cancer is selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, and pituitary cancer.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the cancer is a metastatic cancer.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein said cancer is positive for the mutant estrogen receptor alpha comprising one or more mutations selected from the group consisting of Y537X1, L536X2, P535H, V534E, S463P, V392I, E380Q and combinations thereof, wherein: X1 is S, N, or C, D538G; and X2 is R or Q,

### Claim 6 (depends on 5)

The method of claim 5, wherein the mutation is Y537S.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the ratio of the concentration of RAD1901 or a salt or solvate thereof in the tumor to the concentration of RAD1901 or a salt or solvate thereof in plasma (T/P) following administration is at least about 15.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject has osteoporosis or a higher risk of osteoporosis.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject is a premenopausal woman.

### Claim 10 (depends on 1, 2)

The method of claim 1 or 2, wherein the subject is a postmenopausal woman who had relapsed or progressed after previous treatment with SERMs and/or AIs.

### Claim 11 (depends on 1, 2)

The method of claim 1 or 2, wherein the therapeutically effective amount is about 150 to about 1,500 mg per day.

### Claim 12 (depends on 1, 2)

The method of claim 1 or 2, wherein the salt thereof is RAD1901 dihydrochloride.

### Claim 13 (depends on 1, 2)

The method of claim 1 or 2, wherein the tumor is resistant to a drug selected from the group consisting of anti-estrogens, aromatase inhibitors, and combinations thereof.

### Claim 14 (depends on 12)

The method of claim 12, wherein the anti-estrogen is tamoxifen or fulvestrant.

### Claim 15 (depends on 12)

The method of claim 12, wherein the aromatase inhibitor is aromasin.

### Claim 16 (depends on 1, 2)

The method of claim 1 or 2, wherein the therapeutically effective amount is 150 mg to 2,000 mg.

### Claim 17 (depends on 16)

The method of claim 16, wherein the therapeutically effective amount is 200 mg, 400 mg, or 500 mg.

### Claim 18

A pharmaceutical composition comprising everolimus and RAD1901 or a salt or solvate thereof.

### Claim 19

A method of treating breast cancer in a subject having a drug-resistant estrogen receptor alpha-positive cancer comprising administering to said subject a therapeutically effective amount of a combination of an m-TOR inhibitor and RAD1901 having the structure:
or a salt or solvate thereof.

### Claim 20 (depends on 19)

The method of claim 19 wherein said drug resistant breast cancer is resistant to one or more antiestrogen and/or or aromatase inhibitor therapies.

### Claim 21 (depends on 20)

The method of claim 20 wherein said one or more antiestrogens are selected from the group consisting of tamoxifen, toremifene and fulvestrant and said one or more aromatase inhibitors are selected from the group consisting of aromasin, letrozole and anastrozole.

### Claim 22 (depends on 19, 20, 21)

The method according to any one of claims 19-21 wherein said woman expresses at least one mutant estrogen receptor alpha selected from the group consisting of D538G, Y537S, Y537N, Y537C, E380Q, S463P, L536R, L536Q, P535H, V392I and V534E.

### Claim 23 (depends on 22)

The method of claim 22 wherein said mutant estrogen receptor alpha is selected from the group consisting of Y537S, Y537N, Y537C, D538G, L536R, S463P and E380Q

### Claim 24 (depends on 22, 23)

The method according to claims 22-23 wherein said mutant receptor alpha is Y537S.

### Claim 25 (depends on 19, 20, 21, 22, 23, 24)

The method according to any one of claims 19-24 wherein said RAD1901 is administered in a total daily dosage of from between 100 mg and 1,500 mg.

### Claim 26 (depends on 25)

The method according to claim 25 wherein said RAD1901 is administered in a total daily dosage of from between 100 mg and 1,000 mg.

### Claim 27 (depends on 26)

The method according to claim 26 wherein said RAD1901 is administered in a total daily dosage of 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg or 1,000 mg.

### Claim 28 (depends on 22, 23, 24, 25, 26, 27)

The method according to any one of claims 22-27 wherein said daily dosage is delivered in two separate doses.

### Claim 29 (depends on 28)

The method according to claim 28 wherein said separate doses are equal doses.

### Claim 30 (depends on 29)

The method according to claim 29 wherein said equal doses are 100 mg, 200 mg, 250 mg, 300 mg, 400 mg or 500 mg each.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

The method according to any of claims 25-30 wherein said dosage is delivered by the oral route.

### Claim 32 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claims 19-31 wherein said woman is post-menopausal.

### Claim 33 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method according to any one of claims 19-32 wherein said woman is first identified for treatment through measuring for increased expression of one or more genes selected from ABL1, AKT1, AKT2, ALK, APC, AR, ARID1A, ASXL1, ATM, AURKA, BAP, BAP1, BCL2L11, BCR, BRAF, BRCA1, BRCA2, CCND1, CCND2, CCND3, CCNE1, CDH1, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CEBPA, CTNNB1, DDR2, DNMT3A, E2F3, EGFR, EML4, EPHB2, ERBB2, ERBB3, ESR1, EWSR1, FBXW7, FGF4, FGFR1, FGFR2, FGFR3, FLT3, FRS2, HIF1A, HRAS, IDH1, IDH2, IGF1R, JAK2, KDM6A, KDR, KIFSB, KIT, KRAS, LRP1B, MAP2K1, MAP2K4, MCL1, MDM2, MDM4, MET, MGMT, MLL, MPL, MSH6, MTOR, MYC, NF1, NF2, NKX2-1, NOTCH1, NPM, NRAS, PDGFRA, PIK3CA, PIK3R1, PML, PTEN, PTPRD, RARA, RB1, RET, RICTOR, ROS1, RPTOR, RUNX1, SMAD4, SMARCA4, SOX2, STK11, TET2, TP53, TSC1, TSC2, and VHL.

### Claim 34 (depends on 33)

The method according to claim 33 wherein said one or more genes is selected from AKT1, AKT2, BRAF, CDK4, CDK6, PIK3CA, PIK3R1 and MTOR.

### Claim 35 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method according to any of claims 19-34 wherein said m-TOR inhibitor is selected from the group consisting of sirolimus, temsirolimus, everolimus, and ridafarolimus.

### Claim 36 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method according to claim 19-34 wherein said m-TOR inhibitor is dosed at from between 1 mg and 500 mg daily.

### Claim 37 (depends on 36)

The method according to claim 36 wherein said m-TOR inhibitor is dosed at from between 5 mg and 100 mg daily.

### Claim 38 (depends on 37)

The method according to claim 37 wherein said m-TOR inhibitor is dosed at from between 10 mg and 50 mg daily.

### Claim 39 (depends on 35)

The method according to claim 35 wherein said m-TOR inhibitor is everolimus.

### Claim 40 (depends on 39)

The method according to claim 39 wherein said everolimus is dosed at a daily dose of 10 mg.

### Claim 41 (depends on 39)

The method according to claim 39 wherein said everolimus is dosed at from between 2.5 mg and 7.5 mg.

### Claim 42 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method according to any of claims 19-41 wherein said m-TOR inhibitor is dosed orally.

### Claim 43 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method according to any one of claims 19-42 wherein said m-TOR inhibitor is dosed once per day.
